Results 21 to 30 of about 214,341 (267)

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

Cancer Biology & Medicine, 2022
Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6.
Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen   +7 more
doaj   +1 more source

lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients

Cancer Management and Research, 2022
Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj  

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression

Open Medicine, 2021
Non-small cell lung cancer (NSCLC) is a malignant tumor with the highest mortality rate in our country. It has been found in many studies that microRNA-4521 (miR-4521) is abnormally expressed and plays a role in clear cell renal cell carcinoma and other ...
Sun Butong, Cong Dan, Chen Kang, Bai Yuansong, Li Jun   +4 more
doaj   +1 more source

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

Cancer Management and Research, 2021
Tianxiang Zhang,1 Wei Li,2 Meng Gu,1 Ziyu Wang,1 Shijie Zhou,2 Xuefeng Hao,1 Weiying Li,1 Shaofa Xu1 1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research ...
Zhang T, Li W, Gu M, Wang Z, Zhou S, Hao X, Li W, Xu S   +7 more
doaj  

Targeting AXL in NSCLC

Lung Cancer: Targets and Therapy, 2021
State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these responses are overshadowed by therapy resistance that follows. AXL, a receptor tyrosine kinase with bona fide oncogenic
Zaman,Aubhishek, Bivona,Trever G
openaire   +4 more sources

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

Исследования и практика в медицине, 2021
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov   +5 more
doaj   +1 more source

Pattern of care in locally advanced non-small cell lung cancer: A tertiary care experience from India

Lung India
Introduction and Objective: Heterogeneity in locally advanced (LA) Non-Small Cell Lung Cancer (NSCLC) group necessitates a multi-disciplinary approach to its management. Surgery is the standard of care treatment if resectable; otherwise, concurrent chemo-
Aswin Ravi, Sushmita Pathy, Supriya Mallick, Prabhat S. Malik, Sunil Kumar, Rajeev Kumar   +5 more
doaj   +1 more source

Long Noncoding RNA LINC01426 Sequesters microRNA-519d-5p to Promote Non-Small Cell Lung Cancer Progression by Increasing ETS1 Expression [Retraction]

Cancer Management and Research, 2023
Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708. At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article.
Dai J, Wang B, Zhao Y, Zuo X, Cui H, Chen X, Liu X   +6 more
doaj  

Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To evaluate the prognostic value of CEA, CA125, CA199, NSE, CYFRA21-1 and SCC-Ag as serum tumor markers on the diagnosis of operable non-small cell lung cancer(NSCLC) after radical operation.
LI Shaolei, MA Yuanyuan, XIONG Ying, ZHANG Shanyuan, HUANG Miao, YANG Yue   +5 more
doaj   +1 more source

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

Pharmaceutics, 2020
c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially ...
Nam Ah Kim, Sungyoul Hong, Ki Hyun Kim, Du Hyung Choi, Joo Seok Kim, Kyung Eui Park, Jun Young Choi, Young Kee Shin, Seong Hoon Jeong   +8 more
doaj   +1 more source